Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy

Tumor Biology ◽  
2015 ◽  
Vol 37 (3) ◽  
pp. 3469-3477 ◽  
Author(s):  
Minxiao Yi ◽  
Yang Tang ◽  
Bo Liu ◽  
Qianxia Li ◽  
Xiao Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Genetic Variants ◽  
Radiation Pneumonitis ◽  
Lung Cancer Patients ◽  
Thoracic Radiation

scholarly journals Risk Factors for Radiation Pneumonitis in Lung Cancer Patients with Subclinical Interstitial Lung Disease after Thoracic Radiation Therapy

2021 ◽  
Author(s):  
Fangjuan Li ◽  
Hui Liu ◽  
Hongyu Wu ◽  
Shixiong Liang ◽  
Yaping Xu
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Radiation Pneumonitis ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Lung Cancer Patients ◽  
The Past ◽  
Thoracic Radiation ◽  
Grade 3

Abstract Background: Previous studies have found that patients with subclinical interstitial lung disease (ILD) are more susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. The present study aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy (IMRT) in lung cancer patients with subclinical ILD.Methods: We retrospectively analyzed lung cancer patients with subclinical ILD who were treated with thoracic IMRT with a prescribed dose of ≥50 Gy in our institutions between January 2016 and December 2017.Results: A total of 87 consecutive lung cancer patients with subclinical ILD were selected for the study. The cumulative incidence of grades ≥2 and ≥3 RP at one year was 51.0% and 20.9%, respectively. In the multivariate analysis, the mean lung dose (MLD) ≥12Gy was a significant risk factor for grade ≥2 RP (p = 0.049). Chemotherapy with gemcitabine in the past，V5≥50%，and subclinical ILD involving ≥25% of lung volume were significantly associated with grade ≥3 RP (p = 0.046, p = 0.040, and p = 0.024, respectively).Conclusion: MLD is a significant risk factor for grade ≥2 RP. Lung cancer patients who have received chemotherapy with gemcitabine in the past, V5, and those with subclinical ILD involving ≥25% of lung volume have an increased risk of grade ≥3 RP in lung cancer patients with subclinical ILD.

scholarly journals The TGF-β1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients

2009 ◽  
Vol 4 (1) ◽  
Author(s):  
Ji-Yoon Kim ◽  
Yeon-Sil Kim ◽  
Young-Kyoon Kim ◽  
Hyun-Jin Park ◽  
Seung-Joon Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Radiation Pneumonitis ◽  
Lung Cancer Patients ◽  
Tgf Β1

Exhaled nitric oxide predicts radiation pneumonitis in esophageal and lung cancer patients receiving thoracic radiation

2011 ◽  
Vol 101 (3) ◽  
pp. 443-448 ◽  
Author(s):  
Matthew R. McCurdy ◽  
Mohamad W. Wazni ◽  
Josue Martinez ◽  
Mary Frances McAleer ◽  
Thomas Guerrero
Keyword(s):  
Nitric Oxide ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Radiation Pneumonitis ◽  
Exhaled Nitric Oxide ◽  
Lung Cancer Patients ◽  
Thoracic Radiation
Sign in / Sign up

Export Citation Format

Share Document